AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
The price of failure: Dutch company's chip monopoly born from a bad bet by Intel
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
Cyber unicorn Armis acquiring Silk Security for $150 million
4
BeyondTrust acquiring permissions management startup Entitle for $100-150 million
5
Google employees arrested following protest over Israel ties at executive’s office
More news

Biomed

20 stories about Biomed
צוות עובדי קרטיהיל בישראל

Biomed company CartiHeal acquired by Smith & Nephew for up to $330 million

22.11.23|Meir Orbach
The Israeli firm, which develops a biocompatible, coral-based, off-the-shelf implant for damaged joints, will initially receive $180 million in cash and up to a further $150 million contingent on financial performance
סטיב כהן

Billionaire Steve Cohen leads $27.5 million investment in MediWound

05.02.23|Golan Hazani
Cohen's Point72 hedge fund invested $15 million in the round in what is believed to be the billionaire’s first investment in an Israeli company
Betalin Therapeutics Nikolai Kunicher

Betalin Therapeutics receives EU equity investment for its alternative insulin therapy

21.07.21|James Spiro
The Biomed startup seeks to eliminate the need for insulin injections and glucose testing
מימין דוקטור יהושוע גלייטמן אבנר לושי ופרופסור שלמה נו

Shuki Gleitman's GIBF raising $300 million in China for second biotech fund

31.05.21|Golan Hazani
The Guangzhou Sino-Israel Biotech Investment Fund (GIBF) focuses on life science investments and cooperates with leading Guangzhou organizations to bring Israeli biotech firms to the massive Chinese metropolitan
ד"ר טל זקס מנהל רפואי מודרנה

Moderna’s resigning CMO says he achieved what he cared about

25.02.21|Sophie Shulman
Tal Zaks: I never imagined that I’d develop a vaccine for the worst pandemic of our times
Aya Jakobovitz

Covid-19 was one of the biomed industry’s finest hours, says Israeli Silicon Valley veteran

15.12.20|Ron Friedman
Aya Jakobovits, a trailblazer in the biomed sector who is participating in J-Ventures’ annual investor’s conference, speaks of how the coronavirus vaccines showcased the depth of new technology
קרן אמון מימין ד"ר תומר ברקוביץ ד"ר יאיר שינדל טוד סון איציק דבש

Israel’s aMoon fund saw a 15-fold return on its investment in Seer

09.12.20|Sophie Shulman
aMoon invested in the U.S. biomed company when it was valued at $228 million- after a Nasdaq IPO, its value ballooned to $3.5 billion
שרון מלכה MediWound

Biomed at the focus of new Israel-UAE business cooperation

25.10.20|CTech
New cross-business initiative is led by Tel-Aviv based consultancy firm Kamir Strategy and UAE-based PR firm Cosmopole
קרין מאיר רובינשטיין מנכ"לית IATI

IATI asks government to designate tech and biomed companies as essential industries

24.09.20|Hagar Ravet
Ahead of the second lockdown, tech umbrella group urges decision-makers to allow the industry to keep specialized facilities open
Pitango HealthTech Fund: Ittai Harel (left), Managing Partner; Maya Perl, Principal; Guy Ezekiel,

250 companies and $6.5 billion: An in-depth look at Israel’s healthtech industry

27.08.20|Maya Perl, Ittai Harel, Guy Ezekiel
Israeli healthcare startups are no longer relying solely on technology, clinical data, or IP to generate value. They are reinventing business models and elevating the industry.
בניין ה בורסה משכן חדש רחוב אחוזת בית תל אביב

Biomed Company CartiHeal Considers a Nasdaq IPO

26.02.20|Golan Hazani
The company is looking to raise between $60 million and $80 million according to a valuation of $300 million to $400 million and has already hired Credit Suisse and Jefferies for this purpose, according to two people familiar with the matter
default image

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
default image

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani
Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
עמיר לונדון מנכ"ל קמהדע

FIMI Makes $25 Million Private Placement in Biomed Company Kamada

22.01.20|Tzally Greenberg
Israel-based private equity fund FIMI became the largest shareholder in Nasdaq and Tel Aviv-listed Kamada in November
עובדים ב מפעל של קמהדע

FIMI Becomes Biggest Shareholder in Biomed Company Kamada

24.11.19|Golan Hazani and Tzally Greenberg
Nasdaq and Tel Aviv-listed Kamada develops protein-based pharmaceuticals for genetic disorders, as well as rabies antibodies and a serum against snake bites
default image

Biomed Company BiomX Merges With New York-Listed Chardan Healthcare

17.07.19|Meir Orbach
BiomX develops customized therapies for conditions such as acne and inflammatory bowel disease
אורי קליד פאי תרפיוטיקס Pi Therapeutics

Pi Therapeutics Raises $19.7 Million

29.05.19|Hagar Ravet
Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
לן בלווטניק בעל השליטה בכת"ב

Three Portfolio Companies of Len Blavatnik's Clal Biotechnology Raise Cash in One Week

04.07.18|CTech
Clal Biotechnology Industries is an Israel-based life sciences investment company
נאסד"ק וול סטריט

Fourth Time’s the Charm for Entera Bio IPO

01.07.18|Dror Reich
The Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each
תרופות זירת הבריאות

Entera Bio Gives Nasdaq IPO Another Shot

21.05.18|Dror Reich
This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq
More Articles